Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sorrento Announces Drilling Contract & Receives Permit to Drill Bottom Brook Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Annovis Bio Inc ANVS

Healthcare Biotechnology
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3... see more

Current News (NYSE:ANVS)

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

GlobeNewswire December 18, 2025

Annovis to Host Corporate Update Webinar on January 28, 2026

GlobeNewswire December 16, 2025

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

GlobeNewswire December 3, 2025

Annovis Announces Two Presentations at the CTAD 2025 Conference

GlobeNewswire November 24, 2025

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

GlobeNewswire November 18, 2025

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

GlobeNewswire November 17, 2025

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

GlobeNewswire November 12, 2025

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

GlobeNewswire November 6, 2025

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

GlobeNewswire October 27, 2025
View More News ››

Opinion & Analysis (NYSE:ANVS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSE:ANVS)

Buy buddy buy because it's taking off this morning.

Otherwise FOMO
coolfooldumbguy - November 17, 2025

Buy buddy buy.

Otherwise FOMO
coolfooldumbguy - October 9, 2025

Anyone buying here?

Looking for the bottom.   
mevani - December 29, 2021

ANVS 5 MOST PROMISING ALZHEIMER’S DISEASE STOCK!

5 MOST PROMISING ALZHEIMER’S DISEASE STOCK! https://www.aviseanalytics.com/5-most-promising-alzheimers-disease-stock/
AviseAnalytics - June 22, 2021

CHEMOCENTRYX: A LOT RIDES ON THE APPROVAL OF AVACOPAN

$CCXI CHEMOCENTRYX: A LOT RIDES ON THE APPROVAL OF AVACOPAN
AviseAnalytics - June 21, 2021

CAN ANNOVIS BIO DELIVER A BREAKTHROUGH IN ALZHEIMER’S DISEAS

$ANVS CAN ANNOVIS BIO DELIVER A BREAKTHROUGH IN ALZHEIMER’S DISEASE? https://www.aviseanalytics.com/annovis-bio/
AviseAnalytics - June 18, 2021
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »

Podcasts